DE202010018378U1 - PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1) - Google Patents

PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1) Download PDF

Info

Publication number
DE202010018378U1
DE202010018378U1 DE202010018378.2U DE202010018378U DE202010018378U1 DE 202010018378 U1 DE202010018378 U1 DE 202010018378U1 DE 202010018378 U DE202010018378 U DE 202010018378U DE 202010018378 U1 DE202010018378 U1 DE 202010018378U1
Authority
DE
Germany
Prior art keywords
mmp
par
par1
platelet
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202010018378.2U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
Tufts Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts Medical Center Inc filed Critical Tufts Medical Center Inc
Publication of DE202010018378U1 publication Critical patent/DE202010018378U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE202010018378.2U 2009-04-10 2010-04-12 PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1) Expired - Lifetime DE202010018378U1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16835309P 2009-04-10 2009-04-10
US16836009P 2009-04-10 2009-04-10
US61/168,353 2009-04-10
US61/168,360 2009-04-10

Publications (1)

Publication Number Publication Date
DE202010018378U1 true DE202010018378U1 (de) 2016-04-07

Family

ID=42936908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202010018378.2U Expired - Lifetime DE202010018378U1 (de) 2009-04-10 2010-04-12 PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1)

Country Status (7)

Country Link
US (3) US20120121706A1 (https=)
EP (3) EP2416799B1 (https=)
JP (1) JP2012523438A (https=)
AU (1) AU2010233089B2 (https=)
CA (1) CA2758322C (https=)
DE (1) DE202010018378U1 (https=)
WO (1) WO2010118435A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745347B2 (en) 2010-12-30 2017-08-29 Hadasit Medical Research Services And Development Ltd. PAR1 and PAR2 c-tail peptides and peptide mimetics
EP2606828B1 (en) * 2011-12-20 2018-04-11 Angioclinic AG Hyaluronic acid and its use for treating venous insufficiency and varicose veins
EP2681209B1 (en) * 2011-03-02 2018-05-09 Aquilus Pharmaceuticals, Inc Compounds and methods for the treatment of pain and other disorders
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2013183725A1 (ja) * 2012-06-06 2013-12-12 国立大学法人九州大学 非ヒトモデル動物、非ヒトモデル動物の作製方法及び抗血栓薬のスクリーニング方法
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US9789209B2 (en) * 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015107139A1 (en) * 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
WO2016205062A1 (en) * 2015-06-15 2016-12-22 Shifa Biomedical Corporation Antithrombotic therapies
CN106551944A (zh) * 2015-09-25 2017-04-05 南开大学 四环素类衍生物作为par-1抑制剂的用途
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP7257333B2 (ja) * 2017-12-28 2023-04-13 株式会社カネカ 細胞凝集抑制剤
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
WO2020172113A1 (en) * 2019-02-18 2020-08-27 Lankenau Institute For Medical Research Scar reducing wound closure materials
US11419809B2 (en) 2019-06-27 2022-08-23 L'oreal Hair treatment compositions and methods for treating hair
KR102612229B1 (ko) * 2021-05-21 2023-12-08 가천대학교 산학협력단 N-[(4'-브로모[1,1'-바이페닐]-4-일)설포닐]-l-발린 또는 이의 약제학적으로 허용 가능한 염을 포함하는 아밀로이드 베타의 올리고머화 및 피브릴화 억제용 조성물
US20230011767A1 (en) * 2021-07-09 2023-01-12 Boston Scientific Scimed, Inc. Direct oral anticoagulant-eluting medical device

Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3557280A (en) 1966-05-31 1971-01-19 Koninklijke Gist Spiritus Stable solutions of oxytetracycline suitable for parenteral and peroral administration and process of preparation
US3674859A (en) 1968-06-28 1972-07-04 Pfizer Aqueous doxycycline compositions
US3784701A (en) 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4024272A (en) 1974-09-06 1977-05-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetracyclic compounds
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4529596A (en) 1982-07-13 1985-07-16 Sanofi, S.A. Thieno [3,2-c] pyridine derivatives and their therapeutic application
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4847265A (en) 1987-02-17 1989-07-11 Sanofi Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1991019813A1 (en) 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Nucleic acid ligands
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5283317A (en) 1987-08-03 1994-02-01 Ddi Pharmaceuticals, Inc. Intermediates for conjugation of polypeptides with high molecular weight polyalkylene glycols
US5288726A (en) 1991-09-09 1994-02-22 Ube Industries Limited Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
US5300501A (en) 1990-12-03 1994-04-05 Celltech Limited Peptidyl derivatives
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
WO1995013289A1 (en) 1993-11-10 1995-05-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0451216B1 (en) 1988-12-28 1996-01-24 Protein Design Labs, Inc. Humanized immunoglobulins and their production and use
WO1996011209A1 (en) 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
WO1996015096A1 (en) 1994-11-15 1996-05-23 Bayer Corporation Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
US5525348A (en) 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US5530128A (en) 1992-06-03 1996-06-25 Celltech Therapeutics Limited N-sulphonylamino derivatives of dipetide compounds as metalloproteinase inhibitors
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5631169A (en) 1992-01-17 1997-05-20 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6326155B1 (en) 1995-03-20 2001-12-04 Dyax Corp. Engineering affinity ligands for macromolecules
US6429210B1 (en) 1998-06-15 2002-08-06 Sanofi-Synthelabo Polymorphic clopidogrel hydrogenesulphate form
US6693115B2 (en) 2000-07-06 2004-02-17 Sankyo Company, Limited Acid addition salts of hydropyridine derivatives
US20040127420A1 (en) 2001-08-16 2004-07-01 Stephen Quirk Metalloproteinase inhibitors for wound healing
US20050020607A1 (en) 1999-05-03 2005-01-27 Newton Roger Schofield Statin-MMP inhibitor combinations
US20050191333A1 (en) 2002-08-26 2005-09-01 Biotegra, Inc. Drug eluting coatings for medical implants and methods of use
WO2005097223A1 (en) 2004-03-26 2005-10-20 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
US20060204533A1 (en) 2005-03-14 2006-09-14 Biotegra, Inc. Drug Delivery Compositions and Related Methods
US20070179090A1 (en) 2000-04-21 2007-08-02 Athan Kuliopulos G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
WO2008011107A2 (en) 2006-07-18 2008-01-24 Irm Llc Antagonists of protease activated receptor-1 (par1)
US20090018646A1 (en) 2007-07-10 2009-01-15 Zhao Jonathon Z Coating Employing an Anti-Thrombotic Conjugate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
EP2348047A1 (en) * 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
JP4469467B2 (ja) * 2000-06-29 2010-05-26 帝人株式会社 細胞増殖抑制剤
US20050120392A1 (en) 2002-02-28 2005-06-02 Rubinstein Amy L. Transgenic zebrafish models for thrombosis
AU2004213050B2 (en) * 2003-02-20 2010-09-09 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
US20050025705A1 (en) 2003-07-22 2005-02-03 Xinkang Wang Thrombosis animal models and their use in drug discovery and development
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
CA2843097C (en) * 2005-05-24 2015-10-27 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
US20080214599A1 (en) 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
US20080125354A1 (en) 2005-11-21 2008-05-29 Florida Atlantic University Selective inhibition of matrix metalloproteinases
JP4861115B2 (ja) * 2006-09-28 2012-01-25 サントリーホールディングス株式会社 ラベル、ラベルの製造方法、ラベルの線剥離強度の経時安定化方法、及び容器
US7838232B2 (en) * 2006-10-19 2010-11-23 Auburn University CaIDAG-GEF1 gene mutations associated with thrombopathy in canines
US9719191B2 (en) 2006-11-29 2017-08-01 The Research Foundation For The State University Of New York Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008118320A1 (en) 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US8383156B2 (en) 2007-04-30 2013-02-26 Cordis Corporation Coating for a medical device having an anti-thrombotic conjugate
JP5483023B2 (ja) * 2008-03-27 2014-05-07 国立大学法人東北大学 がん細胞運動およびがん細胞浸潤抑制剤
WO2010119455A2 (en) * 2009-04-15 2010-10-21 Sun Pharma Advanced Research Company Ltd. An injectable sustained release pharmaceutical composition

Patent Citations (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3557280A (en) 1966-05-31 1971-01-19 Koninklijke Gist Spiritus Stable solutions of oxytetracycline suitable for parenteral and peroral administration and process of preparation
US3674859A (en) 1968-06-28 1972-07-04 Pfizer Aqueous doxycycline compositions
US3784701A (en) 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
US4024272A (en) 1974-09-06 1977-05-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetracyclic compounds
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4529596A (en) 1982-07-13 1985-07-16 Sanofi, S.A. Thieno [3,2-c] pyridine derivatives and their therapeutic application
EP0120694B1 (en) 1983-03-25 1993-07-21 Celltech Therapeutics Limited Processes for the production of multichain polypeptides or proteins
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
EP0125023B1 (en) 1983-04-08 1991-06-05 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0194276B1 (en) 1984-09-03 1993-08-11 Celltech Therapeutics Limited Production of chimeric antibodies
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4847265A (en) 1987-02-17 1989-07-11 Sanofi Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
US5283317A (en) 1987-08-03 1994-02-01 Ddi Pharmaceuticals, Inc. Intermediates for conjugation of polypeptides with high molecular weight polyalkylene glycols
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0451216B1 (en) 1988-12-28 1996-01-24 Protein Design Labs, Inc. Humanized immunoglobulins and their production and use
US5525348A (en) 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
WO1991019813A1 (en) 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Nucleic acid ligands
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5300501A (en) 1990-12-03 1994-04-05 Celltech Limited Peptidyl derivatives
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5288726A (en) 1991-09-09 1994-02-22 Ube Industries Limited Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
US5631169A (en) 1992-01-17 1997-05-20 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5530128A (en) 1992-06-03 1996-06-25 Celltech Therapeutics Limited N-sulphonylamino derivatives of dipetide compounds as metalloproteinase inhibitors
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1995013289A1 (en) 1993-11-10 1995-05-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
WO1996011209A1 (en) 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
WO1996015096A1 (en) 1994-11-15 1996-05-23 Bayer Corporation Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
US6326155B1 (en) 1995-03-20 2001-12-04 Dyax Corp. Engineering affinity ligands for macromolecules
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6429210B1 (en) 1998-06-15 2002-08-06 Sanofi-Synthelabo Polymorphic clopidogrel hydrogenesulphate form
US20050020607A1 (en) 1999-05-03 2005-01-27 Newton Roger Schofield Statin-MMP inhibitor combinations
US20070179090A1 (en) 2000-04-21 2007-08-02 Athan Kuliopulos G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US6693115B2 (en) 2000-07-06 2004-02-17 Sankyo Company, Limited Acid addition salts of hydropyridine derivatives
US20040127420A1 (en) 2001-08-16 2004-07-01 Stephen Quirk Metalloproteinase inhibitors for wound healing
US20050191333A1 (en) 2002-08-26 2005-09-01 Biotegra, Inc. Drug eluting coatings for medical implants and methods of use
WO2005097223A1 (en) 2004-03-26 2005-10-20 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
US20060204533A1 (en) 2005-03-14 2006-09-14 Biotegra, Inc. Drug Delivery Compositions and Related Methods
WO2006099514A2 (en) 2005-03-14 2006-09-21 Biotegra, Inc. Drug delivery compositions and related methods
WO2008011107A2 (en) 2006-07-18 2008-01-24 Irm Llc Antagonists of protease activated receptor-1 (par1)
US20090018646A1 (en) 2007-07-10 2009-01-15 Zhao Jonathon Z Coating Employing an Anti-Thrombotic Conjugate

Non-Patent Citations (99)

* Cited by examiner, † Cited by third party
Title
Ausubel et al., Hg., Current Protocols in Molecular Biology, Wiley Interscience, 2006
Ausubel, F. et al., Hg. (1999), Current Protocols in Molecular Biology, J. Wiley: New York
Ausubel, F. et al., Hg., Current Protocols in Molecular Biology 1999, J. Wiley: New York
Bartel et al. (1993) Biotechniques. 14: 920-924
Bergmeier et al., 2003
Bergmeier et al., 2004
Berman et al., 1992
Bhatt und Topol, 2003
Biomol, Kat.-Nr. SE 361
Bird et al., Science, 242: 423-426 (1988)
Boire et al., 2005
Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33: 2061
Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33: 2059
Chang, 1985
Chesney et al., 1974
Cho et al. (1993) Science 261: 1303
Clontech Inc., CA, Gossen und Bujard (1992) Proc. Natl. Acad. Sci. USA 89: 5547
Coughlin, 2000
Covic et al., 2002a
Cull et al. (1992) Proc Natl Acad Sci USA 89: 1865-1869
Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87: 6378-6382
De Witt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90: 6909
Devlin (1990) Science 249: 404-406
Dollery und Libby, 2006
Egeblad und Werb, 2002
Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91: 11422
Felici (1991) J. Mol. Biol. 222: 301-310
Fodor (1993) Nature 364: 555-556
Fressinaud et al., 1992
Furie und Furie, 2008
Gallop et al. (1994) J. Med. Chem. 37: 1233
Galt et al., 2002
Gast et al., 1994
Giesen et al., 1999
Glass und Witztum, 2001
Glassand Witztum, 2001
Gluzman (1981) Cell 123: 175-182
Goeddel, (1990) Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Kalifornien
Gogly et al., 1998
Hage, D. S. und Tweed, S. A. (1997) J Chromatogr B Biomed Sci Appl. 699: 499-525
Heegaard, N. H., (1998) J Mol Recognit 11: 141-8
Houghten (1992) Biotechniques 13: 412-421
Huang et al., 2007
Huebner et al., 1998
Inauen et al., 1990
Jackson et al., 2003
Kaneider et al., 2007
Kazes et al., 2000
Kennebunk, ME
Kuliopulos 1999
Kuliopulos et al., 1999
Kuliopulos et al., 2004
Kuliopulos, 1999
Ladner s. o.
Lam (1991) Nature 354: 82-84
Lam (1997) Anticancer Drug Des. 12: 145
Leger et al., 2006a
Leger et al., 2006b
Levy et al., 2001
Loew et al., 200
Loew et al., 2000
Mackman, 2004
Madura et al. (1993) J. Biol. Chem. 268: 12046-12054
Mann et al., 2007
McConnell, H. M. et al. (1992) Science 257: 1906-1912
Moers et al., 2003
Nelson, A. et al., (2000) J. Clin. Oncol. 18, 1135-1149
Netzel-Arnett et al., 1991
New England Biolabs, Beverly, Mass.
Newman et al., BioTechnology, 10: 1455-1460 (1992)
Offermanns et al., 1994
Okorie et al., 2008
Paillard (1989) Human Gene Therapy 9: 983
Parry et al., 1996
Pearce et al., 2005
Pharmacia Biotech Inc.; Smith, D. B. und Johnson, K. S. (1988) Gene 67: 31-40
Pharmacia, Piscataway, N. J.
Rand et al., 1996
Rivas, G. und Minton, A. P. (1993) Trends Biochem Sci 18: 284-7
Ruggeri, 2002
Sambrook und Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, 2001
Sawicki et al., 1997
Schwertz et al., 2006
Scott und Smith (1990) Science 249: 386-390
Seeley et al., 2003
Sjolander, S., und Urbaniczky, C. (1991) Anal. Chem. 63: 2338-2345
Stephens et al., 2004
Sukhova et al., 1999
Sundaresan und Famdale, 2002
Sundaresan und Farndale, 2002
Szabo et al. (1995) Curr. Opin. Struct. Biol. 5: 699-705
Turk et al., 2001
Veen et al., 1993
Vu et al., 1991
Woessner, J. F. und Nagase, H. (2000) Matrix Metalloproteinases and TIMPs, Oxford University Press, Oxford
Woessner, J. F. und Nagase, H., s. o.
Zervos et al. (1993) Cell 72: 223-232
Zuckermann et al. (1994). J. Med. Chem. 37: 2678
Zuckermann, R. N. et al. (1994) J. Med. Chem. 37: 2678-85

Also Published As

Publication number Publication date
US9376499B2 (en) 2016-06-28
EP2990051B1 (en) 2016-10-26
EP2416799A2 (en) 2012-02-15
WO2010118435A2 (en) 2010-10-14
JP2012523438A (ja) 2012-10-04
EP3061460A1 (en) 2016-08-31
AU2010233089B2 (en) 2016-05-26
EP2990051A1 (en) 2016-03-02
WO2010118435A3 (en) 2011-03-17
US20170065668A1 (en) 2017-03-09
CA2758322C (en) 2019-04-02
EP2416799B1 (en) 2017-11-01
CA2758322A1 (en) 2010-10-14
US20150023975A1 (en) 2015-01-22
EP2416799A4 (en) 2013-04-17
US20120121706A1 (en) 2012-05-17
AU2010233089A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
DE202010018378U1 (de) PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1)
Moncsek et al. Targeting senescent cholangiocytes and activated fibroblasts with B‐cell lymphoma‐extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/−) mice
JP6134268B2 (ja) 創傷治癒を促進するためのグランザイムｂ阻害剤組成物、方法および使用
Abdalla et al. The A kt inhibitor, triciribine, ameliorates chronic hypoxia‐induced vascular pruning and TGF β‐induced pulmonary fibrosis
Fang et al. The adhesion and migration of microglia to β-amyloid (Aβ) is decreased with aging and inhibited by Nogo/NgR pathway
US20230127258A1 (en) Composition comprising thrombin derived peptides and use thereof
WO2015164822A1 (en) Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
EP2205278A1 (en) Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors
Reichenstein et al. Abelson kinases mediate the depression of spontaneous synaptic activity induced by amyloid beta 1–42 peptides
WO2010052715A2 (en) Devices and methods for local treatment of cardiovascular diseases
US8227412B2 (en) Bioactive parstatin peptides and methods of use
US20220195072A1 (en) Targeted anticoagulant
US20090130185A1 (en) Anti-Microbial Compositions Comprising a Cationic Peptide and a Glycylglycine Endopeptidase
WO2008067288A2 (en) Methods for inhibiting foreign body response to implanted materials
US20210238605A1 (en) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
US8399404B2 (en) Methods and uses for inhibiting platelet coagulation
WO2021021716A1 (en) Compositions and methods for inhibiting neointimal formation
JP7025928B2 (ja) 外科的介入後の腹膜の癒着を予防または治療するための医薬組成物および医薬組成物の使用
WO2015009615A1 (en) Methods for the production of collagen iv
US11026992B2 (en) Compositions and methods for preventing and reducing inflammation and treating disorders associated with inflammation
Hubiernatorova et al. Tristetraprolin affects invasion‐associated genes expression and cell motility in triple‐negative breast cancer model
JP2004229547A (ja) アシル化ホモセリンラクトン阻害物質をスクリーニングする方法
Korol The role of cytoskeletal signaling in lens emt
Ishibashi et al. Atg16L1 Protein Regulates Hormone Secretion Independent of Autophagy
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Legal Events

Date Code Title Description
R151 Utility model maintained after payment of second maintenance fee after six years
R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years
R158 Lapse of ip right after 8 years